Parkinson Disease

• 

  Subject Areas on Research

  • 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening. 
  • A Bayesian approach to joint analysis of multivariate longitudinal data and parametric accelerated failure time. 
  • A biophysical model of the cortex-basal ganglia-thalamus network in the 6-OHDA lesioned rat model of Parkinson's disease. 
  • A comparison of an implanted accelerometer with a wearable accelerometer for closed-loop DBS. 
  • A longitudinal evaluation of patients' perceptions of Parkinson's disease. 
  • A novel haplotype-sharing approach for genome-wide case-control association studies implicates the calpastatin gene in Parkinson's disease. 
  • A randomized clinical trial of burst vs. spaced physical therapy for Parkinsons disease. 
  • A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. 
  • A randomized pilot trial of estrogen replacement therapy in post-menopausal women with Parkinson's disease. 
  • A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. 
  • A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. 
  • A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. 
  • Absence of mutation in the beta- and gamma-synuclein genes in familial autosomal dominant Parkinson's disease. 
  • Accounting for linkage in family-based tests of association with missing parental genotypes. 
  • Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. 
  • Activation of neuronal NADPH oxidase NOX2 promotes inflammatory neurodegeneration. 
  • Acute readmission following deep brain stimulation surgery for Parkinson's disease: A nationwide analysis. 
  • Adapters, strugglers, and case managers: a typology of spouse caregivers. 
  • Age at onset in two common neurodegenerative diseases is genetically controlled. 
  • Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). 
  • Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease. 
  • An application of generalizability theory to study a physical performance measure in Parkinson's disease. 
  • Analysis of non-synonymous-coding variants of Parkinson's disease-related pathogenic and susceptibility genes in East Asian populations. 
  • Analysis of the time course of the effect of subthalamic nucleus stimulation upon hand function in Parkinson's patients. 
  • Anhedonia in Japanese patients with Parkinson's disease: analysis using the Snaith-Hamilton Pleasure Scale. 
  • Apolipoprotein E and neuromuscular disease: a critical review of the literature. 
  • Apolipoprotein E controls the risk and age at onset of Parkinson disease. 
  • Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. 
  • Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease. 
  • Application of longitudinal item response theory models to modeling Parkinson's disease progression. 
  • Association between pathologic gambling and parkinsonian therapy as detected in the Food and Drug Administration Adverse Event database. 
  • Association between the neuron-specific RNA-binding protein ELAVL4 and Parkinson disease. 
  • Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression. 
  • Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores. 
  • Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. 
  • Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. 
  • Association test for X-linked QTL in family-based designs. 
  • Augmented Beta rectangular regression models: A Bayesian perspective. 
  • Automated Deep Brain Stimulation Programming for Tremor. 
  • Automated deep brain stimulation programming with safety constraints for tremor suppression in patients with Parkinson's disease and essential tremor. 
  • Automatic localization of the subthalamic nucleus on patient-specific clinical MRI by incorporating 7 T MRI and machine learning: Application in deep brain stimulation. 
  • Bayesian hierarchical model for multiple repeated measures and survival data: an application to Parkinson's disease. 
  • Bayesian semiparametric multiple shrinkage. 
  • Bee Venom Acupuncture in Addition to Anti-Parkinsonian Medications may Improve Activities of Daily Living and Motor Symptoms More Than Medication Alone in Idiopathic Parkinson's Disease. 
  • Before and after the veterans affairs cooperative program 468 study: Deep brain stimulator target selection for treatment of Parkinson's disease. 
  • Bilateral Subthalamic Nucleus Deep Brain Stimulation in Elderly Patients With Parkinson Disease: A Case-Control Study. 
  • Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy. 
  • Caught in the act: LRRK2 in exosomes. 
  • Cerebral mitochondrial metabolism in early Parkinson's disease. 
  • Characterization of Retinal Microvascular and Choroidal Structural Changes in Parkinson Disease. 
  • Characterization of Small-Molecule-Induced Changes in Parkinson's-Related Trafficking via the Nedd4 Ubiquitin Signaling Cascade. 
  • Characterization of pallidocortical motor network in Parkinson's disease through complex network analysis. 
  • Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum. 
  • Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and parkin gene mutations. 
  • Coenzyme Q10: a review of its promise as a neuroprotectant. 
  • Comparing self-reported and objective monitoring of physical activity in Parkinson disease. 
  • Comparison of Bilateral vs. Staged Unilateral Deep Brain Stimulation (DBS) in Parkinson's Disease in Patients Under 70 Years of Age. 
  • Comparison of Deep Brain Stimulation Lead Targeting Accuracy and Procedure Duration between 1.5- and 3-Tesla Interventional Magnetic Resonance Imaging Systems: An Initial 12-Month Experience. 
  • Complete genomic screen in Parkinson disease: evidence for multiple genes. 
  • Complex relationship between Parkin mutations and Parkinson disease. 
  • Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies. 
  • Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders. 
  • Consensus-based clinical practice recommendations for the examination and management of falls in patients with Parkinson's disease. 
  • Continuous deep brain stimulation of the subthalamic nucleus may not modulate beta bursts in patients with Parkinson's disease. 
  • Contribution of neuropsychiatric symptoms in Parkinson's disease to different domains of caregiver burden. 
  • Convergence of Parkin, PINK1, and α-Synuclein on Stress-induced Mitochondrial Morphological Remodeling. 
  • Coronal plane spinal malalignment and Parkinson's disease: prevalence and associations with disease severity. 
  • Correlates of care relationship mutuality among carers of people with Alzheimer's and Parkinson's disease. 
  • Correlation between symptoms and function in older adults with comorbidity. 
  • Correlation of diffusion tensor tractography and intraoperative macrostimulation during deep brain stimulation for Parkinson disease. 
  • Cross-Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease. 
  • Current therapy of Parkinson's disease. 
  • DNA damage and repair in Parkinson's disease: Recent advances and new opportunities. 
  • Daytime sleepiness and other sleep disorders in Parkinson's disease. 
  • Deciding to institutionalize: why do family members cease caregiving at home? 
  • Deconstructing behavioral neuropharmacology with cellular specificity. 
  • Deep brain stimulation alleviates parkinsonian bradykinesia by regularizing pallidal activity. 
  • Deep brain stimulation for Parkinson disease in elderly individuals—reply. 
  • Deep brain stimulation that abolishes Parkinsonian activity in basal ganglia improves thalamic relay fidelity in a computational circuit. 
  • Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. 
  • Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. 
  • Developmental exposure to organophosphates triggers transcriptional changes in genes associated with Parkinson's disease in vitro and in vivo. 
  • Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. 
  • Differential attrition in a caregiver skill training trial. 
  • Diminished subcortical nuclei volumes in Parkinson's disease by MR imaging. 
  • Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. 
  • Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy. 
  • Distinct neurological disorders with ATP1A3 mutations. 
  • Do P1 and N1 evoked by the ERP task reflect primary visual processing in Parkinson's disease? 
  • Do nurse-led skill training interventions affect informal caregivers' out-of-pocket expenditures? 
  • Dopamine Transporter Imaging has no Impact on Functional Outcomes in de Novo Probable Parkinson's Disease. 
  • Dopamine agonists and the suppression of impulsive motor actions in Parkinson disease. 
  • Dopamine and α-synuclein dysfunction in Smad3 null mice. 
  • Dopamine modulates the response of the human amygdala: a study in Parkinson's disease. 
  • Dopaminergic control of sleep-wake states. 
  • Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity. 
  • Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD. 
  • Dyskinesias associated with lithium therapy in parkinsonism. 
  • ECT-induced delirium in depressed patients with Parkinson's disease. 
  • Early sensory information processes are enhanced on visual oddball and S1-S2 tasks in Parkinson's disease: a visual event-related potentials study. 
  • Editor's Highlight: Base Excision Repair Variants and Pesticide Exposure Increase Parkinson's Disease Risk. 
  • Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. 
  • Effect of advancing age on outcomes of deep brain stimulation for Parkinson disease. 
  • Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. 
  • Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. 
  • Effect of interstimulus interval on visual P300 in Parkinson's disease. 
  • Effects of repetitive transcranial magnetic stimulation on motor symptoms in Parkinson disease: a systematic review and meta-analysis. 
  • Electrical stimulation of the dorsal columns of the spinal cord for Parkinson's disease. 
  • Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers. 
  • Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease. 
  • Enhancing case ascertainment of Parkinson's disease using Medicare claims data in a population-based cohort: the Cardiovascular Health Study. 
  • Enhancing the efficiency of direct reprogramming of human primary fibroblasts into dopaminergic neuron-like cells through p53 suppression. 
  • Ensemble recordings of human subcortical neurons as a source of motor control signals for a brain-machine interface. 
  • Environmental exposures in elderly Canadians with Parkinson's disease. 
  • Erythromelalgia-like eruption in parkinsonian patients treated with bromocriptine. 
  • Etiology of Parkinson's disease: Genetics and environment revisited. 
  • Evidence for Compartmentalized Axonal Mitochondrial Biogenesis: Mitochondrial DNA Replication Increases in Distal Axons As an Early Response to Parkinson's Disease-Relevant Stress. 
  • Evoked potentials generated by deep brain stimulation for Parkinson's disease. 
  • Evoked potentials reveal neural circuits engaged by human deep brain stimulation. 
  • Exercise to improve spinal flexibility and function for people with Parkinson's disease: a randomized, controlled trial. 
  • Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. 
  • Exposure to low-dose ambient fine particulate matter PM2.5 and Alzheimer's disease, non-Alzheimer's dementia, and Parkinson's disease in North Carolina. 
  • Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. 
  • Extensive uptake of α-synuclein oligomers in astrocytes results in sustained intracellular deposits and mitochondrial damage. 
  • Factors related to extended hospital stays following deep brain stimulation for Parkinson's disease. 
  • Falling down the digital divide: A cautionary tale. 
  • Familial aggregation of multiple myeloma and central nervous system diseases. 
  • Family-based case-control study of MAOA and MAOB polymorphisms in Parkinson disease. 
  • Family-based case-control study of cigarette smoking and Parkinson disease. 
  • Fe(III)-coordination properties of neuromelanin components: 5,6-dihydroxyindole and 5,6-dihydroxyindole-2-carboxylic acid. 
  • Feasibility of using ultra-high field (7 T) MRI for clinical surgical targeting. 
  • Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. 
  • Finding useful biomarkers for Parkinson's disease. 
  • Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. 
  • Formation of α-synuclein Lewy neurite-like aggregates in axons impedes the transport of distinct endosomes. 
  • Freezing of Gait in Parkinson's Disease: Invasive and Noninvasive Neuromodulation. 
  • Fruit flies, bile acids, and Parkinson disease: a mitochondrial connection? 
  • Functional association of the parkin gene promoter with idiopathic Parkinson's disease. 
  • GDNF in treatment of Parkinson's disease: response to editorial. 
  • GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. 
  • Gait initiation in community-dwelling adults with Parkinson disease: comparison with older and younger adults without the disease. 
  • Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale. 
  • Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. 
  • Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. 
  • Gene- and cell-based approaches for neurodegenerative disease. 
  • Gene-gene interaction between FGF20 and MAOB in Parkinson disease. 
  • Genetic Defects in Mitochondrial Dynamics in Caenorhabditis elegans Impact Ultraviolet C Radiation- and 6-hydroxydopamine-Induced Neurodegeneration. 
  • Genetic analysis of α-synuclein 3' untranslated region and its corresponding microRNAs in relation to Parkinson's disease compared to dementia with Lewy bodies. 
  • Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation. 
  • Genetic complexity and Parkinson's disease. Deane Laboratory Parkinson Disease Research Group. 
  • Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. 
  • Genetics of parkin-linked disease. 
  • Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases. 
  • Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. 
  • Genome-wide association study of Parkinson's disease in East Asians. 
  • Genome-wide linkage screen in familial Parkinson disease identifies loci on chromosomes 3 and 18. 
  • Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra. 
  • Genomic convergence: identifying candidate genes for Parkinson's disease by combining serial analysis of gene expression and genetic linkage. 
  • Glucocerebrosidase gene mutations associated with Parkinson's disease: a meta-analysis in a Chinese population. 
  • Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. 
  • Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. 
  • High-frequency stimulation of the subthalamic nucleus reverses limb-use asymmetry in rats with unilateral 6-hydroxydopamine lesions. 
  • Identification and characterization of the human parkin gene promoter. 
  • Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort. 
  • Identification of a novel gene linked to parkin via a bi-directional promoter. 
  • Identification of bona-fide LRRK2 kinase substrates. 
  • Identification of risk and age-at-onset genes on chromosome 1p in Parkinson disease. 
  • Identifying Peripapillary Radial Capillary Plexus Alterations in Parkinson's Disease Using OCT Angiography. 
  • Impact of Movement Disorders on Management of Spinal Deformity in the Elderly. 
  • Impact of Parkinson's disease on continence after radical prostatectomy. 
  • Improved efficacy of temporally non-regular deep brain stimulation in Parkinson's disease. 
  • In-Hospital Complications and Resource Utilization Following Lumbar Spine Surgery in Patients with Parkinson Disease: Evaluation of the National Inpatient Sample Database. 
  • Induction of the protective antioxidant response element pathway by 6-hydroxydopamine in vivo and in vitro. 
  • Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein. 
  • Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. 
  • Initial Clinical Outcome With Bilateral, Dual-Target Deep Brain Stimulation Trial in Parkinson Disease Using Summit RC + S. 
  • Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience. 
  • Investigation of the PARK10 gene in Parkinson disease. 
  • It Is as It Was: MDS-UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum. 
  • Item Response Theory Analysis of the MDS-UPDRS Motor Examination: Tremor vs. Nontremor Items. 
  • LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease. 
  • LRRK2 activation in idiopathic Parkinson's disease. 
  • LRRK2 in Parkinson's disease: function in cells and neurodegeneration. 
  • LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. 
  • Lessons learned from a Parkinson's disease caregiver intervention pilot study. 
  • Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration. 
  • Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. 
  • Levodopa inhalation powder in a patient with persistent asthma. 
  • Linkage disequilibrium and haplotype tagging polymorphisms in the Tau H1 haplotype. 
  • Linkage of Parkinsonism and Alzheimer's disease with Lewy body pathology to chromosome 12. 
  • Linking a genome-wide association study signal to a LRRK2 coding variant in Parkinson's disease. 
  • Longitudinal evaluation of economic and physical impact of Parkinson's disease. 
  • M1 and M2 immune activation in Parkinson's Disease: Foe and ally? 
  • Magnetic resonance evaluation of the midbrain in Parkinson's disease. 
  • Management of patients with Parkinson disease. 
  • Managing the patient with Parkinson's disease. 
  • Measures of shoulder protraction and thoracolumbar rotation. 
  • Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. 
  • Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. 
  • Microelectrode Recordings Validate the Clinical Visualization of Subthalamic-Nucleus Based on 7T Magnetic Resonance Imaging and Machine Learning for Deep Brain Stimulation Surgery. 
  • Mindfulness based stress reduction in people with Parkinson's disease and their care partners. 
  • Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease. 
  • Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease. 
  • Mitochondrial dynamics and Parkinson's disease: focus on parkin. 
  • Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. 
  • Molecular Features Underlying Neurodegeneration Identified through In Vitro Modeling of Genetically Diverse Parkinson's Disease Patients. 
  • Molecular markers of early Parkinson's disease based on gene expression in blood. 
  • Molecular pathophysiology of Parkinson's disease. 
  • Morphometry of the human substantia nigra in ageing and Parkinson's disease. 
  • Multiplication of the SNCA locus exacerbates neuronal nuclear aging. 
  • N-myc regulates parkin expression. 
  • NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats. 
  • NOS2A and the modulating effect of cigarette smoking in Parkinson's disease. 
  • Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. 
  • Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA). 
  • Neuropathological features of frontotemporal dementia and parkinsonism linked to chromosome 17q21-22 (FTDP-17): Duke Family 1684. 
  • Neuropsychiatric Issues in Parkinson's Disease. 
  • Neuropsychological and psychiatric sequelae of pallidotomy for PD: clinical trial findings. 
  • Nicotine as a therapeutic drug. 
  • Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. 
  • Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease. 
  • No association between Parkinson disease alleles and the risk of melanoma. 
  • Novel genetic loci underlying human intracranial volume identified through genome-wide association. 
  • Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. 
  • Ocular signs of brain stimulation in the human. 
  • Optimized temporal pattern of brain stimulation designed by computational evolution. 
  • Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity. 
  • Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. 
  • PD-linked CHCHD2 mutations impair CHCHD10 and MICOS complex leading to mitochondria dysfunction. 
  • PET studies of cerebral metabolism in Parkinson disease. 
  • PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. 
  • Palliative treatment of dysphonia and dysarthria. 
  • Parkin mediates the degradation-independent ubiquitination of Hsp70. 
  • Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. 
  • Parkin-proven disease: common founders but divergent phenotypes. 
  • Parkinson disease and the immune system - associations, mechanisms and therapeutics. 
  • Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. 
  • Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program. 
  • Parkinson's disease from the gut. 
  • Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research. 
  • Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. 
  • Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. 
  • Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain. 
  • Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease. 
  • Patient-specific anatomical model for deep brain stimulation based on 7 Tesla MRI. 
  • Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease. 
  • Patterns of chronic venous insufficiency in the dural sinuses and extracranial draining veins and their relationship with white matter hyperintensities for patients with Parkinson's disease. 
  • Peripheral Klotho and Parkinson's Disease. 
  • Pesticide exposure and risk of Parkinson's disease: a family-based case-control study. 
  • Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations. 
  • Phosphorylation-dependent metal binding by alpha-synuclein peptide fragments. 
  • Physical Activity in Early Parkinson Disease. 
  • Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. 
  • Platelet mitochondrial complex I and I+III activities do not correlate with cerebral mitochondrial oxidative metabolism. 
  • Potential mechanisms for low uric acid in Parkinson disease. 
  • Predicting Parkinson's disease trajectory using clinical and neuroimaging baseline measures. 
  • Predictors of weight loss in Parkinson's disease. 
  • Prevalence and type of cervical deformities among adults with Parkinson's disease: a cross-sectional study. 
  • Prevalence of radiological and clinical cerebrovascular disease in idiopathic Parkinson's disease. 
  • Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change. 
  • Proteomic analysis of urinary extracellular vesicles reveal biomarkers for neurologic disease. 
  • Psychosis in Parkinson's disease: diagnosis and treatment. 
  • Quality Control in Neurons: Mitophagy and Other Selective Autophagy Mechanisms. 
  • Quality of life and Parkinson's disease. 
  • Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2. 
  • Racial and Ethnic Differences in Health-Related Quality of Life for Individuals With Parkinson Disease Across Centers of Excellence. 
  • Ranbp2 haploinsufficiency mediates distinct cellular and biochemical phenotypes in brain and retinal dopaminergic and glia cells elicited by the Parkinsonian neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). 
  • Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. 
  • Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. 
  • Rankin scale as a potential measure of global disability in early Parkinson's disease. 
  • Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction. 
  • Refinement of the PARK3 locus on chromosome 2p13 and the analysis of 14 candidate genes. 
  • Regular Exercise, Quality of Life, and Mobility in Parkinson's Disease: A Longitudinal Analysis of National Parkinson Foundation Quality Improvement Initiative Data. 
  • Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene. 
  • Regulation of alpha-synuclein expression: implications for Parkinson's disease. 
  • Reliability of impairment and physical performance measures for persons with Parkinson's disease. 
  • Reliability of physical performance tests in four different randomized clinical trials. 
  • Repetitive transcranial magnetic stimulation to SMA worsens complex movements in Parkinson's disease. 
  • Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine. 
  • Restoration of locomotive function in Parkinson's disease by spinal cord stimulation: mechanistic approach. 
  • Resurgence of stereotaxic procedures for relief of parkinsonism. Role of image-directed targeting and current status. 
  • Retinal Microvascular and Choroidal Changes in Parkinson Disease-Reply. 
  • Revealing the role of glutathione S-transferase omega in age-at-onset of Alzheimer and Parkinson diseases. 
  • Revelations and revolutions in the understanding of Parkinson's disease. 
  • Robust Bayesian inference for multivariate longitudinal data by using normal/independent distributions. 
  • Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. 
  • SLC1A2 variant associated with essential tremor but not Parkinson disease in Chinese subjects. 
  • SNPs in CAST are associated with Parkinson disease: a confirmation study. 
  • STN-ANT plasticity is crucial for the motor control in Parkinson's disease model. 
  • Safety considerations for deep brain stimulation: review and analysis. 
  • Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. 
  • Sagittal spinopelvic malalignment in Parkinson disease: prevalence and associations with disease severity. 
  • Scientific and ethical concerns in neural fetal tissue transplantation. 
  • Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease. 
  • Serum Lymphocyte-Associated Cytokine Concentrations Change More Rapidly over Time in Multiple System Atrophy Compared to Parkinson Disease. 
  • Single-cell redox imaging demonstrates a distinctive response of dopaminergic neurons to oxidative insults. 
  • Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. 
  • Somatic Mutations in LRRK2 Identify a Subset of Invasive Mammary Carcinomas Associated with High Mutation Burden. 
  • Speech motor program maintenance, but not switching, is enhanced by left-hemispheric deep brain stimulation in Parkinson's disease. 
  • Spinal cord stimulation alleviates motor deficits in a primate model of Parkinson disease. 
  • Spinal cord stimulation failed to relieve akinesia or restore locomotion in Parkinson disease. 
  • Spinal cord stimulation restores locomotion in animal models of Parkinson's disease. 
  • Spinal flexibility and balance control among community-dwelling adults with and without Parkinson's disease. 
  • Spinal movement and performance of a standing reach task in participants with and without Parkinson disease. 
  • Structural variants can be more informative for disease diagnostics, prognostics and translation than current SNP mapping and exon sequencing. 
  • Structural variants in SNCA gene and the implication to synucleinopathies. 
  • Subcortical neuronal ensembles: an analysis of motor task association, tremor, oscillations, and synchrony in human patients. 
  • Successful use of the Unified Dyskinesia Rating Scale regardless of PD- or dyskinesia-duration. 
  • Surgical Treatment of Parkinson Disease. 
  • Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production. 
  • Technology of deep brain stimulation: current status and future directions. 
  • Ten years and counting: moving leucine-rich repeat kinase 2 inhibitors to the clinic. 
  • Thalamic projections to the subthalamic nucleus contribute to movement initiation and rescue of parkinsonian symptoms. 
  • The Aryl Hydrocarbon Receptor: A Mediator and Potential Therapeutic Target for Ocular and Non-Ocular Neurodegenerative Diseases. 
  • The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part IX. A prospective cliniconeuropathologic study of Parkinson's features in Alzheimer's disease. 
  • The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins. 
  • The Impact of Environmental Factors on Monogenic Mendelian Diseases. 
  • The NINDS Parkinson's disease biomarkers program. 
  • The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models. 
  • The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. 
  • The burden of Parkinson's disease on society, family, and the individual. 
  • The cell and molecular biology of glaucoma: common neurodegenerative pathways and relevance to glaucoma. 
  • The correlation between P300 alterations and regional cerebral blood flow in non-demented Parkinson's disease. 
  • The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. 
  • The effect of SNCA 3' region on the levels of SNCA-112 splicing variant. 
  • The effect of tremorine on dopamine concentration in the brain of the rat, guinea pig and rabbit. 
  • The effect of unilateral electrostimulation of the subthalamic nucleus on respiratory/phonatory subsystems of speech production in Parkinson's disease--a preliminary report. 
  • The experience of care partners of patients with Parkinson's disease psychosis. 
  • The future of implantable neuroprosthetic devices: ethical considerations. 
  • The genetic architecture of the human cerebral cortex. 
  • The importance of preclinical diagnostics in Parkinson disease. 
  • The interplay between monocytes, α-synuclein and LRRK2 in Parkinson's disease. 
  • The mechanistic role of alpha-synuclein in the nucleus: impaired nuclear function caused by familial Parkinson's disease SNCA mutations. 
  • The nature and scope of stressful spousal caregiving relationships. 
  • The role of alpha-synuclein in Parkinson's disease: insights from animal models. 
  • The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease. 
  • The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease. 
  • Therapeutic application of repetitive transcranial magnetic stimulation: a review. 
  • To die or grow: Parkinson's disease and cancer. 
  • Toward deciphering the mechanistic role of variations in the Rep1 repeat site in the transcription regulation of SNCA gene. 
  • Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. 
  • Treatment of depression in the medically ill. 
  • Triggers and alleviating factors for fatigue in Parkinson's disease. 
  • Uncovering the dynamics of a circadian-dopamine model influenced by the light-dark cycle. 
  • Understanding physical activity in Veterans with Parkinson disease: A mixed-methods approach. 
  • Understanding the Lexicon of Fatigue in Parkinson's Disease. 
  • Untwisted α-Synuclein Filaments Formed in the Presence of Lipid Vesicles. 
  • Up-regulation of SNCA gene expression: implications to synucleinopathies. 
  • Usefulness of Blood Pressure Variability Indices Derived From 24-Hour Ambulatory Blood Pressure Monitoring in Detecting Autonomic Failure. 
  • Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings. 
  • Validation of the Arabic Version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. 
  • Validation of the Hebrew Version of the Unified Dyskinesia Rating Scale. 
  • Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. 
  • Validation of the Polish version of the Unified Dyskinesia Rating Scale (UDysRS). 
  • Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. 
  • Virtual Reality Functional Capacity Assessment Tool (VRFCAT-SL) in Parkinson's Disease. 
  • Visual event-related potential changes at two different tasks in nondemented Parkinson's disease. 
  • Visual event-related potentials in progressive supranuclear palsy, corticobasal degeneration, striatonigral degeneration, and Parkinson's disease. 
  • Visual event-related potentials under different interstimulus intervals in Parkinson's disease: relation to motor disability, WAIS-R, and regional cerebral blood flow. 
  • Who to Enroll in Parkinson Disease Prevention Trials? The Case for Genetically At-Risk Cohorts. 
  • Why are you calling me? How study introductions change response patterns. 
  • X-APL: an improved family-based test of association in the presence of linkage for the X chromosome. 
  • X-LRT: a likelihood approach to estimate genetic risks and test association with X-linked markers using a case-parents design. 
  • Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. 
  • alpha-Synuclein gene haplotypes are associated with Parkinson's disease. 
  • α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration. 
• 

  Keywords of People

  • Anderson, Ruth A., Professor Emerita in the School of Nursing, School of Nursing
  • Cohen, Seth Morris, Professor of Head and Neck Surgery & Communication Sciences, Head and Neck Surgery & Communication Sciences
  • Ferreira, Paulo Alexandre, Associate Professor in Ophthalmology, Pathology
  • Li, Yi-Ju, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • McConnell, Eleanor Schildwachter, Associate Professor in the School of Nursing, School of Nursing
  • Nicolelis, Miguel Angelo L., Duke School of Medicine Distinguished Professor in Neuroscience, Neurobiology
  • Turner, Dennis Alan, Professor of Neurosurgery, Biomedical Engineering
  • Xiao, Ran, Assistant Consulting Professor in the School of Nursing, School of Nursing